Alkem Laboratories Ltd (ALKEM)

Alkem Laboratories Dividend Reduced, But Sustainability Looks Good - 13 Jul, 2024

Alkem Laboratories' dividend has been reduced to ₹5.00, but earnings easily cover the payout and next year's EPS is set to grow by 45.6%. The estimated payout ratio of 21% makes us comfortable with the sustainability of the dividend, although past inconsistency raises some concerns. Overall, Alkem Laboratories has potential for future dividend growth.

ICICI Direct Research Recommends Alkem Laboratories as a Buy - 10 Jul, 2024

Alkem Laboratories has been recommended as a buy by ICICI Direct Research, with a target price of ₹ 5410 and a stop loss of ₹ 4874.9. The current momentum in the pharma sector presents a favorable risk-reward scenario for potential upward movement.

Alkem Laboratories Ltd Up for Fifth Straight Session - 09 Jul, 2024

Alkem Laboratories Ltd stock is up 1.82% on the day, quoting at Rs 5317.1 as of 12:44 IST on NSE. The company has risen around 5.68% in the last month and is up 52.46% in the last year. The PE ratio of the stock is 34.68 based on TTM earnings ending March 24.

Alkem Laboratories Ltd Up 1.34% on NSE - 05 Jul, 2024

Alkem Laboratories Ltd is up 1.34% on the NSE, trading at Rs 5048.25 as of 12:49 IST. The stock has gained 43.28% in the last year compared to a 24.53% gain in NIFTY and a 47.56% gain in the Nifty Pharma index.

Alkem Laboratories Plans to Double US Revenue by 2020 and Launch IPO - 28 Jun, 2024

Alkem Laboratories plans to double its US revenue by 2020 through expanding its generic portfolio, commercializing more ANDAs, and in-licensing deals. The company also plans to launch an IPO in December, offering 12.85 million equity shares and raising $210-220 million.

Alkem Laboratories Cuts Dividend, but Potential for Growth Remains - 27 Jun, 2024

Despite reducing its dividend to ₹5.00, Alkem Laboratories has the potential for growth with a forecasted EPS expansion of 46.8%. The payout ratio is expected to be sustainable at 21% next year. While cuts are concerning, the company's earnings per share have grown by 19% annually over the past five years. Overall, it could be a good dividend opportunity.

Alkem Labs Promoter Sells Stake; Revenue & Profits Decline - 26 Jun, 2024

Seema Singh, promoter of Alkem Laboratories, sold shares worth Rs. 177 crore via block deal while the company's revenue fell by 12% and net profits declined by 50% from Dec '23 to Mar '24. However, profitability metrics improved. The USFDA issued a VAI EIR for its manufacturing facility in Baddi, HP.

Alkem Labs Receives EIR From USFDA and Proposes Dividend - 25 Jun, 2024

Alkem Laboratories received an establishment inspection report from USFDA for its manufacturing facility in Baddi, Himachal Pradesh, leading to a 4.77% increase in shares. The board proposed a final dividend of ₹5 per equity share of ₹2 each for FY24. Promoter Seema Singh sold shares worth Rs 177 crore through an open market transaction.

Alkem Labs Stock Sees Mixed Day on Sales and Profit Reports - 18 Jun, 2024

Alkem Laboratories Ltd saw mixed results in its stock market performance as it reported a slight increase in net sales and profits for March 2024 while also experiencing a drop in stock prices due to a large sale of shares. However, the stock rebounded later in the day following another sale of shares.